Apr 8, 2025
In today’s episode, we discuss nervous system repair in the context of traumatic injury and disease with Mike Kelly, the President and CEO of NervGen. With more than three decades of pharmaceutical experience under his belt, Mike plays instrumental roles in the creation, development, and strengthening of a number of pharma companies.
What’s his primary goal? To constantly innovate medical technology for people across the globe…
NervGen is a clinical-stage
biotech company advancing innovative therapies for treatments for
nervous
system damage. Their lead drug candidate, NVG-291, is currently
being evaluated in a Phase 1b/2a clinical trial for spinal cord
injury. Additionally, they have launched preclinical evaluation for
NVG-300 – a new development candidate, in models of ischemic
stroke, amyotrophic lateral sclerosis (ALS), and spinal cord
injury.
Hit play to find out:
- Where NervGen’s technology comes from.
- What nervous system regeneration looks like at a molecular level.
- How clinical trials progress from animals to humans.
- The ways that biomarker results can indicate breakthroughs in science.
Be sure to follow along with
NerGen’s cutting-edge work by visiting their website!
Episode also available on Apple Podcast: http://apple.co/30PvU9C
Boost Your Brainpower with 15% OFF!
Fuel
your mind with BrainSupreme Supplements and unlock your
full potential. Get 15% OFF your order now using this
exclusive link: brainsupreme.co/
Hurry—your brain deserves the best!